Advances in Biomarkers and Endogenous Regulation of Breast Cancer Stem Cells

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Oct 14

PMID 36230903

Authors

Wenmin Chen

Lu Zhang

Suling Liu

Ceshi Chen

Affiliations

Soon will be listed here.

Abstract

Breast cancer is one of the most common cancers. Even if breast cancer patients initially respond to treatment, developed resistance can lead to a poor prognosis. Cancer stem cells (CSCs) are a group of undifferentiated cells with self-renewal and multipotent differentiation characteristics. Existing evidence has shown that CSCs are one of the determinants that contribute to the heterogeneity of primary tumors. The emergence of CSCs causes tumor recurrence, metastasis, and therapeutic resistance. Previous studies indicated that different stemness-associated surface markers can identify other breast cancer stem cell (BCSC) subpopulations. Deciphering the critical signaling networks that are involved in the induction and maintenance of stemness is essential to develop novel BCSC-targeting strategies. In this review, we reviewed the biomarkers of BCSCs, critical regulators of BCSCs, and the signaling networks that regulate the stemness of BCSCs.

Citing Articles

A Tumor Microenvironment-Driven Network Regulated by STAT3 and p65 Negatively Controls the Enrichment of Cancer Stem Cells in Human HR+/HER2- Breast Cancer.

Ben-Yaakov H, Meshel T, Pasmanik-Chor M, Korner C, Ben-Baruch A Cancers (Basel). 2023; 15(8).

PMID: 37190183 PMC: 10137120. DOI: 10.3390/cancers15082255.

References

Zhi X, Zhao D, Zhou Z, Liu R, Chen C . YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. Am J Pathol. 2012; 180(6):2452-61. DOI: 10.1016/j.ajpath.2012.02.025. View

Meng Z, Liu Y, Wang J, Fan H, Fang H, Li S . Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer. J Cell Physiol. 2019; 235(2):932-943. DOI: 10.1002/jcp.29008. View

Liu H, Song Y, Qiu H, Liu Y, Luo K, Yi Y . Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death Differ. 2019; 27(3):966-983. PMC: 7206060. DOI: 10.1038/s41418-019-0389-3. View

Liu S, Lee J, Jie C, Park M, Iwakura Y, Patel Y . HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance. Cancer Res. 2018; 78(8):2040-2051. PMC: 5899630. DOI: 10.1158/0008-5472.CAN-17-2761. View

Zhao Q, Liu Y, Wang T, Yang Y, Ni H, Liu H . MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. Eur J Pharmacol. 2020; 884:173359. DOI: 10.1016/j.ejphar.2020.173359. View

Wang X, Reyes M, Zhang D, Funakoshi Y, Trape A, Gong Y . EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget. 2017; 8(40):67904-67917. PMC: 5620223. DOI: 10.18632/oncotarget.18958. View

Polytarchou C, Iliopoulos D, Struhl K . An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S A. 2012; 109(36):14470-5. PMC: 3437881. DOI: 10.1073/pnas.1212811109. View

Lattouf H, Kassem L, Jacquemetton J, Choucair A, Poulard C, Tredan O . LKB1 regulates PRMT5 activity in breast cancer. Int J Cancer. 2018; 144(3):595-606. PMC: 6294691. DOI: 10.1002/ijc.31909. View

Zhang H, Li N, Zhang J, Jin F, Shan M, Qin J . The influence of miR-34a expression on stemness and cytotoxic susceptibility of breast cancer stem cells. Cancer Biol Ther. 2016; 17(6):614-24. PMC: 4990398. DOI: 10.1080/15384047.2016.1177678. View

10.

Vazquez-Santillan K, Melendez-Zajgla J, Jimenez-Hernandez L, Gaytan-Cervantes J, Munoz-Galindo L, Pina-Sanchez P . NF-kappaΒ-inducing kinase regulates stem cell phenotype in breast cancer. Sci Rep. 2016; 6:37340. PMC: 5120353. DOI: 10.1038/srep37340. View

11.

Xiang L, Gilkes D, Hu H, Takano N, Luo W, Lu H . Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget. 2015; 5(24):12509-27. PMC: 4350363. DOI: 10.18632/oncotarget.2997. View

12.

Liu Z, Zhang W, Phillips J, Arora R, McClellan S, Li J . Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. Oncogene. 2018; 38(1):88-102. PMC: 6318029. DOI: 10.1038/s41388-018-0407-9. View

13.

Shi P, Liu W, Tala , Wang H, Li F, Zhang H . Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov. 2017; 3:17010. PMC: 5396048. DOI: 10.1038/celldisc.2017.10. View

14.

Peng F, Li T, Wang K, Xiao G, Wang J, Zhao H . H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis. 2017; 8(1):e2569. PMC: 5386357. DOI: 10.1038/cddis.2016.438. View

15.

Debeb B, Lacerda L, Xu W, Larson R, Solley T, Atkinson R . Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling. Stem Cells. 2012; 30(11):2366-77. PMC: 4545658. DOI: 10.1002/stem.1219. View

16.

Zeng L, Cen Y, Chen J . Long non-coding RNA MALAT-1 contributes to maintenance of stem cell-like phenotypes in breast cancer cells. Oncol Lett. 2018; 15(2):2117-2122. PMC: 5777122. DOI: 10.3892/ol.2017.7557. View

17.

Sobecki M, Mrouj K, Camasses A, Parisis N, Nicolas E, Lleres D . The cell proliferation antigen Ki-67 organises heterochromatin. Elife. 2016; 5:e13722. PMC: 4841783. DOI: 10.7554/eLife.13722. View

18.

Barker A, Sigman C, Kelloff G, Hylton N, Berry D, Esserman L . I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009; 86(1):97-100. DOI: 10.1038/clpt.2009.68. View

19.

Hu T, Liu S, Breiter D, Wang F, Tang Y, Sun S . Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 2008; 68(16):6533-40. DOI: 10.1158/0008-5472.CAN-07-6642. View

20.

Mimoto R, Imawari Y, Hirooka S, Takeyama H, Yoshida K . Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer. Oncogene. 2016; 36(13):1862-1872. DOI: 10.1038/onc.2016.349. View